Guillain-Barre syndrome following autologous bone marrow transplantation

Raja Mudad, A. Hussein, W. P. Peters

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The pathogenesis of the Guillain-Barre syndrome (GBS) is felt to involve alterations in cellular and humoral immune responses. We report the case of a 44-year-old female with stage IV breast cancer who developed GBS 2 days after receiving high dose chemotherapy with bone marrow and peripheral progenitor cell support, and granulocyte-macrophage colony stimulating factor (GM-CSF). Her clinical status stabilized with plasmapheresis. This report lends further support to hypotheses regarding cellular immune alterations in the pathogenesis of GBS.

Original languageEnglish (US)
Pages (from-to)167-169
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume18
Issue number2
StatePublished - 1995
Externally publishedYes

Fingerprint

Guillain-Barre Syndrome
Autologous Transplantation
Bone Marrow Transplantation
Plasmapheresis
Granulocyte-Macrophage Colony-Stimulating Factor
Humoral Immunity
Cellular Immunity
Stem Cells
Bone Marrow
Breast Neoplasms
Drug Therapy

Keywords

  • Bone marrow transplantation
  • Guillain-Barre syndrome
  • Stage IV breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Guillain-Barre syndrome following autologous bone marrow transplantation. / Mudad, Raja; Hussein, A.; Peters, W. P.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 18, No. 2, 1995, p. 167-169.

Research output: Contribution to journalArticle

@article{bf605f85dafd434a862e4c2c1a443f0b,
title = "Guillain-Barre syndrome following autologous bone marrow transplantation",
abstract = "The pathogenesis of the Guillain-Barre syndrome (GBS) is felt to involve alterations in cellular and humoral immune responses. We report the case of a 44-year-old female with stage IV breast cancer who developed GBS 2 days after receiving high dose chemotherapy with bone marrow and peripheral progenitor cell support, and granulocyte-macrophage colony stimulating factor (GM-CSF). Her clinical status stabilized with plasmapheresis. This report lends further support to hypotheses regarding cellular immune alterations in the pathogenesis of GBS.",
keywords = "Bone marrow transplantation, Guillain-Barre syndrome, Stage IV breast cancer",
author = "Raja Mudad and A. Hussein and Peters, {W. P.}",
year = "1995",
language = "English (US)",
volume = "18",
pages = "167--169",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Guillain-Barre syndrome following autologous bone marrow transplantation

AU - Mudad, Raja

AU - Hussein, A.

AU - Peters, W. P.

PY - 1995

Y1 - 1995

N2 - The pathogenesis of the Guillain-Barre syndrome (GBS) is felt to involve alterations in cellular and humoral immune responses. We report the case of a 44-year-old female with stage IV breast cancer who developed GBS 2 days after receiving high dose chemotherapy with bone marrow and peripheral progenitor cell support, and granulocyte-macrophage colony stimulating factor (GM-CSF). Her clinical status stabilized with plasmapheresis. This report lends further support to hypotheses regarding cellular immune alterations in the pathogenesis of GBS.

AB - The pathogenesis of the Guillain-Barre syndrome (GBS) is felt to involve alterations in cellular and humoral immune responses. We report the case of a 44-year-old female with stage IV breast cancer who developed GBS 2 days after receiving high dose chemotherapy with bone marrow and peripheral progenitor cell support, and granulocyte-macrophage colony stimulating factor (GM-CSF). Her clinical status stabilized with plasmapheresis. This report lends further support to hypotheses regarding cellular immune alterations in the pathogenesis of GBS.

KW - Bone marrow transplantation

KW - Guillain-Barre syndrome

KW - Stage IV breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0028901953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028901953&partnerID=8YFLogxK

M3 - Article

C2 - 7900710

AN - SCOPUS:0028901953

VL - 18

SP - 167

EP - 169

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -